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Background: The aim of the present study was to investigate within ovarian carcinoma and normal ovarian
biopsies the gene expression of multiple secretoglobin family members relative to mammaglobin B, which we
previously reported as a promising novel ovarian carcinoma prognostic marker.
Methods: Using quantitative real-time Reverse Transcription PCR we tested 53 ovarian carcinoma and 30 normal
ovaries for the expression of 8 genes belonging to the secretoglobin family: mammaglobin A, lipophilin A,
lipophilin B, uteroglobin, HIN-1, UGRP-1, RYD5 and IIS. Next, we decided to expand the LipB gene expression
analysis to a further 48 ovarian carcinoma samples, for a total of 101 tumor tissues of various histologies and to
study its protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tumors and normal
ovaries. Finally, we correlated lipophilin B gene and protein expression to conventional patient clinico-pathological
features and outcome.
Results: We found significant mammaglobin A, lipophilin A, lipophilin B and RYD5 gene overexpression in ovarian
carcinomas compared to normal ovaries. Lipophilin B mRNA showed a higher presence in tumors (75.4%)
compared to normal ovaries (16.6%) and the most significant correlation with mammaglobin B mRNA (rs =0.77,
p < 0.001). By immunohistochemical analysis, we showed higher lipophilin B expression in the cytoplasm of
tumor cells compared to normal ovaries (p < 0.001). Moreover, lipophilin B gene overexpression was significantly
associated with serous histology (serous vs clear cell p = 0.027; serous vs undifferentiated p = 0.007) and lower
tumor grade (p = 0.02). Lower LipB mRNA levels (low versus high tertiles) were associated to a shorter
progression-free (p = 0.03, HR = 2.2) and disease-free survival (p = 0.02, HR = 2.5) by univariate survival analysis
and, importantly, they remain an independent prognostic marker for decreased disease-free (p = 0.001, HR = 3.9)
and progression-free survival (p = 0.004, HR = 2.8) in multivariate Cox regression analysis.
Conclusions: The present study represents the first quantitative evaluation of secretoglobin gene expression in
normal and neoplastic ovarian tissues. Our results demonstrate lipophilin B gene and protein upregulation in
ovarian carcinoma compared to normal ovary. Moreover, lipophilin B gene overexpression correlates with a less
aggressive tumor phenotype and represents a novel ovarian carcinoma prognostic factor.
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Epithelial ovarian cancer (EOC) represents the fifth lead-
ing cause of cancer deaths among women, with 65,538
estimated new cases and 42,704 deaths in Europe during
the 2012 [1]. The high mortality rate of EOC reflects its
asymptomatic nature, a lack of adequate screening tests,
the frequent diagnosis at late stage, and the frequency of
chemoresistant recurrences [2]. Unfortunately, EOC is
fundamentally an incurable disease, and currently avail-
able prognostic parameters are not able to adequately
predict its relapse and clinical course [3]. There is a crit-
ical need to discover outcome-informative biomarkers to
select those EOC patients who might benefit from indi-
vidualized targeted therapies.
Secretoglobins are secreted proteins of small molecu-
lar weight belonging to a polypeptide family that in-
cludes at least nine family members in humans:
SCGB1A1 (Uteroglobin or Clara cell 10 kDa protein
[CC10]), SCGB1C1 (ligand binding protein RYD5 [RYD5]),
SCGB1D1 (lipophilin A [LipA]), SCGB1D2 (lipophilin B
[LipB] or BU101), SCGB1D4 (interferon-γ inducible SCGB
[IIS]), SCGB2A1 (mammaglobin 2 [MGB2] or lipophilin
C), SCGB2A2 (mammaglobin 1 [MGB1] or uteroglobin
2 [UGB2]), SCGB3A1 (uteroglobin-related protein 2
[UGRP2] or high-in-normal [HIN1]) and SCGB3A2
(uteroglobin-related protein 1 [UGRP1]) [4-7]. Al-
though the first secretoglobin polypeptide was discov-
ered more than 30 years ago, the pathophysiological
functions of the family are still poorly known.
Secretoglobin expression has generally been observed
in secretory epithelia [8-11] and their dysregulated ex-
pression has been reported in several malignancies,
such as lung [12-14], pituitary [15], breast [16,17] and
gynecological cancers [18-20].
Our group has recently reported mammaglobin B
(MGB2) as highly expressed both at the gene and pro-
tein level in EOC tissues [21,22]. Moreover, in a subse-
quent study we demonstrated that MGB2 expression
characterizes a less aggressive EOC phenotype and is
correlated with reduced risk of recurrence, suggesting its
promising role as a novel marker for EOC prognosis [23].
To the best of our knowledge, no studies have extensively
investigated the gene expression of secretoglobins in EOC
tissues and normal ovarian controls. Because of this lack
of information, in the present study we quantified for the
first time gene expression of all prominent human
secretoglobin family members in a panel of fresh-frozen
EOC and normal ovarian biopsies. Since lipophilin B
(LipB) mRNA showed the highest correlation with MGB2,
we further validated LipB gene expression in an expanded
set of samples and, subsequently, LipB protein expression
by immunohistochemistry. Finally, we correlated LipB
gene and protein expression to conventional clinicopatho-
logical features and outcome endpoints in a selectedgroup of homogeneously-treated EOC patients to deter-
mine its prognostic significance in EOC.
Methods
Patients
Cancer tissue samples were obtained from 101 patients
diagnosed with EOC and treated at the Division of Gy-
necologic Oncology of the University of Brescia (Italy),
between June 2003 and December 2010. The study has
been performed following the Declaration of Helsinki set
of principles and it has been approved by the Research
Review Board- the Ethic Committee- of the Spedali
Civili, Brescia, Italy (study reference number: 527/B4/4).
Each patient underwent primary cytoreductive sur-
gery including total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy and pelvic and
periaortic lymph node sampling, with cytological
evaluation of ascites or peritoneal washings. Age,
histological type, stage, grade, residual tumor, presence
of ascites and lymph node involvement were recorded
in all cases. Tumor staging was in accordance with the
International Federation of Gynecology and Obstetrics
(FIGO) criteria, while tumor grade and histological type
were determined following World Health Organization
(WHO) standards; optimal cytoreduction was defined as
no macroscopic residual tumor after primary surgery
(RT = 0).
Ninety-two EOC patients received the same postoper-
ative platinum-based chemotherapy and were included
in survival analysis. Specifically, 80% of patients received
carboplatin and paclitaxel-combined regimen, 15% were
treated with carboplatin only and the remaining 5% of
patients had a platinum-based regimen combined with
other drugs (i.e. topotecan, gemcitabine). Patients were
followed from the date of surgery until death or the last
observation (median follow-up 39 months, range = 7–
93 months). At the time of last follow-up, 31 patients
(34%) were alive without evidence of disease, 15 patients
(16%) were alive with disease and 46 patients (50%) were
dead of disease.
Tissue collection and establishment of HOSE cell lines
All EOC specimens were collected and immediately fro-
zen as previously described [21]. Only samples containing
at least 70% of tumor epithelial cells as assessed by a staff
pathologist were used for total RNA extraction.
Control specimens included 10 normal human ovarian
surface epithelial short-term cultures (HOSE), 10 fresh-
frozen normal ovarian biopsies and 10 normal ovarian
surface epithelium brushings. HOSE were cultured from
normal ovaries of patients undergoing hysterectomy and
bilateral salpingo-oophorectomy for benign pathologies,
as previously reported [21] and only cell cultures
containing at least 99% epithelial cells were retained for
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sharply macrodissected and immediately frozen in liquid
nitrogen. Ovarian brushings were performed on the
whole normal ovary with a cell culture scraper in phos-
phate buffered saline (PBS) and cells were collected by
centrifugation at 1000 rpm for 10 minutes. The cell pel-
let was then resuspended with 200 μl TRIzol Reagent
(Invitrogen life Technologies, Carlsbad, CA, USA)
and immediately frozen at −20°C for further RNA
extraction.
Total RNA extraction and quantitative real-time reverse
transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted and purified from 101 EOC
tissues with different histologies, 10 HOSE, 10 fresh-
frozen normal ovarian biopsies and 10 normal ovarian
surface brushings. Total RNA extraction and quality
control were performed as previously reported [21].
Since HIN-1 assay (Hs00369360_g1) is designed with se-
quences that are complementary also to genomic DNA,
RNA samples were treated with TURBO DNase enzyme
(TURBO DNA-free Kit; Ambion, Inc. Applied Biosystem
Business, CA) to remove contaminating DNA eventually
present. In particular, four μg of total RNA were
digested with 2U of TURBO DNase enzyme in a 25 μl-
reaction for 30 minutes at 37°C. The digestion was
stopped by adding 2.5 μl of DNase Inactivation Reagent,
followed by centrifugation. One μg of extracted RNA
was reverse-transcribed using random hexamers in a
final volume of 20 μl according to the SuperScript TM II
RT RnaseH-reverse transcriptase protocol (Invitrogen
life Technologies, Carlsbad, CA, USA).
QRT-PCR was performed on the ABI PRISM 7000 Se-
quence detection System (Applied Biosystem, Applera
UK, Cheshire, UK) using the TaqMan Universal PCR mas-
ter mix and the following Assay on Demand primers and
probes (Applied Biosystem): Hs00255208_m1 (lipophilin
B), Hs00267190_m1 (mammaglobin A), Hs00255210_m1
(lipophilin A), Hs00171092_m1 (uteroglobin), Hs00369360_g1
(HIN-1), Hs00369678_m1 (UGRP-1), Hs00377337_m1
(SCGB1C1) and Hs00419570_m1 (SCGB1D4). Reaction
and thermal cycling conditions were performed as previ-
ously reported [21]. The comparative threshold cycle (Ct)
method was used for the calculation of amplification
fold and the delta-delta Ct method was used to obtain
relative gene expression values, normalized using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as an internal control.
Immunohistochemistry on formalin-fixed tissues
Immunohistochemistry (IHC) was performed on 100
formalin fixed-paraffin embedded EOC tissues of differ-
ent histologies and 10 normal ovaries. Both tumor and
normal samples were matched with the ones analyzed atthe mRNA level by qRT-PCR. Antigen retrieval was
performed in EDTA buffer pH 8 by using microwave at
750 W. Anti-lipophilin B antibody diluted 1:10 (S-17
goat polyclonal antibody, Santa Cruz Biotechnology, Inc,
Santa Cruz, CA, USA) was applied for 45 minutes,
followed by a secondary biotinylated anti-goat antibody
diluted 1:20 (Vector Laboratories, Burlingame, CA) and
the streptavidin-biotin complex (StreptABComplex/HRP,
Dako, CA, USA). 3’3-diaminobenzidine (Dako, CA,
USA) was used as chromogen and the sections were
counterstained by hematoxylin (Dako).
Slides were analyzed at medium/high power view (20x
and 40x magnification) and a scoring method based ei-
ther on the intensity of the staining or on the percentage
of positive tumor cells was applied as follows: intensity
was scored 0 (negative), 1 (weak), 2 (moderate), 3
(strong), while percentage of positive cells was scored as
0 (0%), 1 (1-10%), 2 (11-50%), 3 (51-100%). A single
scale with scores 0–9 was obtained multiplying the in-
tensity and the percentage staining score and a total
score was calculated grouping score 0 in total score 0,
1–3 in total score 1, 4 and 6 in total score 2 and 9 in
total score 3.
Statistical analysis
The variation in secretoglobin gene expression measured
by qRT-PCR between EOCs and healthy controls and
among EOC histotypes was evaluated using Wilcoxon-
Mann–Whitney test and a standard parametric ANOVA,
respectively. The difference in LipB immunohistochemi-
cal staining between groups, considered on the ordinal
scale, was investigated using Wilcoxon-Mann–Whitney
test and with a nonparametric one-way ANOVA. Ap-
proximate p-values were computed through Monte
Carlo resampling (using B = 9999 replications). Multiple
comparison correction was applied for paired tests using
a step-down procedure. The correlation between LipB
expression measured by qRT-PCR and IHC staining was
evaluated by means of the polyserial correlation coeffi-
cient. The association between LipB mRNA expression
and clinicopathologic parameters was investigated with
an ANOVA (after log transformation). The association
between IHC, coded as ≤1, 2 and 3 and clinical covari-
ates were evaluated by means of Kruskal-Wallis and
Wilcoxon-Mann-Whithney tests. For survival analysis,
three endpoints (cancer relapse, cancer progression and
death due to cancer) were used to calculate disease-free
survival (DFS), progression-free survival (PFS) and
disease-specific overall survival (OS), respectively. DFS
was defined as the time interval between the date of sur-
gery and the date of identification of disease recurrence,
PFS was defined as the time interval between the date of
surgery and the date of identification of progressive dis-
ease (disease not treatable with curative intent) and OS
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gery and the date of death. For all three endpoints the
last date of follow-up was used for censored subjects.
Survival models were fitted using the Cox proportional
hazard model, while survival curves were drawn based
on the Kaplan-Meier methods. The impact of LipB qRT-
PCR expression on prognosis was evaluated categorizing
the qRT-PCR values in tertiles computed on the whole
cohort (Low: <891; Medium: 891–1782.9;? High: >
1782.9) while immunostaining was analyzed both as a
continuous variable and by group (≤1, 2 and 3). Optimal
threshold in ROC curve was computed as the marker
value that minimizes the distance from the top left cor-
ner (sensitivity & specificity equal to 100%) and the
curve. In all analyses, a p value <0.05 was considered sig-
nificant. All statistical analyses were performed using the
R language.
Results
Evaluation of secretoglobin gene expression by qRT-PCR
Secretoglobin gene expression was evaluated on 53 EOC
tissues and 30 normal controls (NO), including 10 HOSE,
10 fresh-frozen normal ovarian biopsies and 10 normal
ovarian surface epithelium brushings. As displayed inTable 1 Distribution of secretoglobin mRNA expression in no
and correlation with MGB2 gene expression*
Secretoglobin % expressing Relative
express
Mean (
SCGB2A1 (Mammaglobin B) EOC 46/53 = 86.7% 186883.
NO 2/23 = 8.6% 1432.00
SCGB2A2 (Mammaglobin A) EOC 36/53 = 67.9% 23295.4
NO 2/30 = 6.6% 0.37 (0.3
SCGB1D1 (Lipophilin A) EOC 40/53 = 75.4% 4741.58
NO 2/30 = 6.6% 5.83 (4.1
SCGB1D2 (Lipophilin B) EOC 40/53 = 75.4% 122631.
NO 5/30 = 16.6% 3818.80
SCGB3A1 (HIN-1) EOC 8/53 = 15.1% 386,48 (
NO 3/30 = 10.0% 2194.48
SCGB1C1 (RYD5) EOC 37/53 = 69.8% 57.79
(26.83)
NO 3/30 = 10% 2.70 (2.1
SCGB1D4 (IIS) EOC 29/53 = 54.7% 72084.2
NO 10/26 = 38.4% 340.77 (
SCGB1A1 (Uteroglobin) EOC 11/53 = 20.7% 138.72 (
NO 5/30 = 16.6% 185.43 (
SCGB3A2 (UGRP-1) EOC 6/53 = 11.3% 2.85 (1.6
NO 1/30 = 3.3% 0.17 (0.1
* The p value indicates significance in the difference between NO and EOC for each
Rho cc = Spearman Rho correlation coefficient).Table 1, there was no difference in gene expression be-
tween EOC and NO for uteroglobin, HIN-1, UGRP-1 and
IIS. Conversely, RYD5, mammaglobin A, lipophilin A, and
lipophilin B genes were overexpressed in EOCs compared
to NO. The optimal cut-off point of positivity in gene ex-
pression for each secretoglobin was determined by means
of a receiver operating characteristic curve, and it was set
at relative quantification = 0.5 for uteroglobin, UGRP-1,
IIS, RYD5, mammaglobin A and lipophilin A, at relative
quantification = 2.5 for HIN-1, at relative quantification =
2559.5 for mammaglobin B and, finally, at relative quanti-
fication = 2520.5 for Lipophilin B.
LipB mRNA showed the most significant correlation
with mammaglobin B mRNA (rs =0.77, p < 0.001), the
expression of which was previously published by our
group on the same cohort of patients [23] (reported in
Table 1 in the present study). LipB mRNA was highly
expressed in EOC (75.4%) compared to normal controls
(16.6%). Consequently, we decided to expand the LipB
qRT-PCR analysis to further 48 EOC samples, for a total
of 101 tumor tissues of various histologies, and its
overexpression was confirmed in ovarian tumor tissues
compared to healthy controls (fold change = 84.8; p <
0.001), as displayed in Figure 1. According to the chosenrmal ovaries (NO) and epithelial ovarian cancers (EOC)
mRNA
ion
p value Correlation with
SCGB2A1 gene
expressionSD)
Rho cc p value
54 (63045.00)
p < 0.001 1 -
(648.59)
2 (21171.01)
p < 0.001 0.63 p < 0.001
3)
(2680.96)
p < 0.001 0.66 p < 0.001
9)
77 (48990.82)
p < 0.001 0.77 p < 0.001
(1908.12)
1606,95)
p = 0.21 0.39 p < 0.001
(6305.41)
p < 0.001 0.36 p < 0.001
4)
3 (69346.5)
p = 0.411 0.50 p < 0.001
158.75)
117.09)
p = 0.452 0.25 p = 0.03
116.76)
5)
p = 0.190 0.16 p = 0.17
6)
secretoglobin mRNA expression (ns = not significant, SD = standard deviation,
Figure 1 Lipophilin B mRNA relative expression in epithelial
ovarian cancers (EOC) compared to normal ovaries (NO). LipB
qRT-PCR analysis in a total of 101 EOCs of various histologies and in
30 NOs confirmed its overexpression in tumor tissues compared to
healthy controls (fold change = 84.8; p < 0.001).
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ples were positive for LipB mRNA expression. The sensi-
tivity and specificity of the test were therefore 80.8% and
83.3%, respectively.
Validation of LipB protein expression by
immunohistochemical staining
To confirm LipB gene expression at the protein level,
immunohistochemistry was carried out on 100 primary
EOCs of different histological types and 10 normal ovar-
ies. Cytoplasmatic staining for LipB was detected in 95
out of 100 (95%) ovarian cancer specimens (Figure 2B),
with the majority of primary EOCs (59%) showing a
strong to moderate staining (score 2 and 3, Table 2). OnFigure 2 Lipophilin B immunohistochemical staining in epithelial ova
Immunohistochemistry showed no expression in normal ovaries (A), while
carcinoma cells (B).the contrary, none of the 10 normal ovaries showed any
immunoreactivity for LipB, neither in the surface epithe-
lium nor in the stroma (Figure 2A). In all EOCs, LipB
immunoreactivity localized exclusively to the cytoplasm
of neoplastic epithelium; stromal cells were negative. No
significant difference in LipB protein expression among
different EOC histotypes was found. Finally, the correl-
ation between LipB mRNA expression and IHC staining
performed in paired tumor samples was not significant
(p = 0.811).LipB expression and clinicopathologic variables
No significant correlation was found between LipB protein
expression and clinicopathological variables (Table 2),
however, LipB gene overexpression was significantly asso-
ciated with lower tumor grade (p = 0.02) and histological
type (Table 3). In particular, LipB gene expression was sig-
nificantly higher in serous EOC compared to clear cell
histotype and in serous and mixed tumors compared to
undifferentiated histotype (Figure 3, p = 0.027, p = 0.007
and p = 0.036, respectively).LipB expression and patient survival
As expected, known EOC clinical prognostic factors
such as FIGO stage, residual tumor, presence of ascites
and lymph node involvement showed a statistically sig-
nificant association with DFS and PFS in univariate sur-
vival analyses (all p < 0.05, Table 4), demonstrative of the
representative nature of the patient cohort recruited in
this study. In addition, as displayed in Figure 4A and 4B
respectively, lower LipB mRNA levels (low versus high
tertiles) showed a significant association with poor DFS
(p = 0.02) and shorter PFS (p = 0.03). FIGO stage, re-
sidual tumor, presence of ascites and lymph node in-
volvement were of prognostic significance for disease-
specific OS, whereas LipB gene expression was not. No
significant correlation was found between LipB immuno-
histochemical staining and survival variables (Table 4).rian cancers (EOC) compared to normal ovaries (NO).
it displayed a predominant staining in the cytoplasm of ovarian
Table 2 Clinico-pathologic characteristics of 100 EOC
patients and their association to LipB protein expression
LipB protein expression
Total score ≤ 1 score = 2 score = 3 p-value
n(%) n(%) n(%)
Age at diagnosis (y)
≤60 48 22 (46) 20 (42) 6 (12) 0.6
>60 52 19 (37) 25 (48) 8 (15)
Histological type
serous 51 25 (49) 17 (33) 9 (18)
endometrioid 17 5 (29) 11 (65) 1 (6)
clear cell 11 6 (55) 3 (27) 2 (18)
mucinous 3 0 1 (33) 2 (67) 0.3
mixed 13 4 (31) 9 (69) 0
undifferentiated 5 1 (20) 4 (80) 0
FIGO stage
I + II 27 10 (37) 13 (48) 4 (15)
III + IV 73 31 (42) 32 (44) 10 (14) 0.7
Histological grade
G1 5 1 (20) 2 (40) 2 (40)
G2 + G3 95 40 (42) 43 (45) 12 (13) 0.2
Residual tumor
(RT), cm
RT = 0 40 14 (35) 21 (52) 5 (13)
RT > 0 60 27 (45) 24 (40) 9 (15) 0.5
Presence of ascites
no 44 19 (43) 18 (41) 7 (16)
yes 56 22 (39) 27 (48) 7 (13) 0.5
Lymph nodal
involvement
negative 51 16 (31) 23 (45) 12 (24)
positive 26 13 (50) 12 (46) 1 (4) 0.3
missing 23 12 (52) 10 (44) 1 (4)
Table 3 Clinico-pathologic characteristics of 101 EOC
patients and their association with LipB mRNA
expression
Parameters Fold change 95%CI p-value
Histological type
Serous vs endometrioid 0.84 0.25-2.22 0.773
Serous vs clear cell 3.43 0.002-0.79 0.027
Serous vs mucinous 1756 0.66-3.83 0.345
Serous vs mixed 1.05 0.51-2.34 0.533
Serous vs undifferentiated 12.99 1.80-7.88 0.007
Endometrioid vs clear cell 4.04 0.66-2.83 0.265
Endometrioid vs mucinous 2069 0.46-3.73 0.487
Endometrioid vs mixed 1.24 0.27-2.32 0.765
Endometrioid vs undifferentiated 15.31 0.96-1.73 0.094
Clear cell vs mucinous 511 0.36-3.52 0.446
Clear cell vs undifferentiated 3.78 0.46-2.94 0.269
Mixed vs clear cell 3.25 0.71-3.72 0.151
Mixed vs mucinous 1660 0.36-3.54 0.412
Mixed vs undifferentiated 12.28 0.007-0.89 0.036
Undifferentiated vs mucinous 135 0.22-3.77 0.990
Histological grade
G2 + G3 vs G1 0.04 0.003-0.59 0.02
FIGO stage
III + IV vs I + II 0.80 0.29-2.14 0.66
Age at diagnosis (y)
>60 vs ≤60 1.09 0.512-2.335 0.58
Residual tumor (RT), cm
RT > 0 vs RT = 0 0.99 0.41-2.38 0.99
Presence of ascites
yes vs no 1.69 0.76-3.73 0.19
Lymph node involvement
positive vs negative 1.03 0.42-2.52 0.94
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gene expression levels were then included in a multivari-
ate survival analysis. As displayed in Table 4, low LipB
mRNA expression and the established prognostic factors
for EOC were identified as independent predictors for
poor DFS (all p ≤ 0.02). Moreover, low LipB mRNA ex-
pression level, along with advanced FIGO stage, retained
significance as an independent prognostic factor for
shorter PFS (p = 0.004, Table 4). For OS, only FIGO stage
was significantly predictive; among the other clinical pa-
rameters, LipB mRNA expression levels exhibited the
highest trend toward significance (p = 0.103, Table 4).
Discussion
Secretoglobins are small, secreted proteins increasingly
recognized for their prognostic capacity in a variety ofhuman cancers, though the precise pathophysiologic func-
tions for most members remain to be elucidated [24].
Secretoglobins participate via one to three cysteine bonds
in antiparallel heterodimerization (e.g., lipophilin B with
mammaglobin A and B) [25-27]. or homodimerization
(e.g., uteroglobin) with the capacity to form tetramers
[10]. Such quaternary protein interactions underscore
the importance of simultaneous characterization of the
relative expression among multiple secretoglobin pro-
teins. Thus, to complement previous findings by our
group in EOC, suggesting that elevated mammaglobin
B gene and protein expression prognosticate improved
clinical outcome [23], in this report we describe for the
first time relative expression patterns across a compre-
hensive panel of human secretoglobin family members.
Secretoglobin gene expression was evaluated on 53
Figure 3 Lipophilin B mRNA relative expression in EOC different histotypes. LipB expression was significantly higher in serous and mixed
tumors compared to undifferentiated histotype (p = 0.007 and p = 0.036, respectively) and in serous tumors compared to clear cell
histotype (p = 0.027).
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controls (NO), including 10 HOSE, 10 fresh-frozen
normal ovarian biopsies and 10 normal ovarian surface
epithelium brushings. The choice of normal controls
in ovarian carcinoma gene expression studies is still a
matter of debate, since the origin and pathogenesis of
this neoplasm is not completely understood.
In the present paper, we have chosen to use ovarian
surface epithelial cells as controls, following the long
lasting theory that, for a significant number of ovarian
cancers, the pathogenesis is related to the invagination
of the ovarian surface epithelium (OSE) at the time of
ovulation into the underlying stroma to form inclusion
cysts with a newly acquired müllerian phenotype (by
metaplasia), as precursors of most of the ovarian cancer
subtypes studied in our manuscript [28,29]. Consistent
with this view, a recent report [30] has identified a spe-
cific transitional area of the OSE, as a previously
unrecognized stem cell niche that can be susceptible to
malignant transformation, providing additional implica-
tions for understanding ovarian carcinoma pathogenesis.
For all these reasons we believe the controls used in our
study are reasonable and in agreement with the current
ovarian cancer literature.
In our analysis, compared to normal ovarian tissues,
EOC specimens overexpressed mammaglobin A, lipophilin
A, lipophilin B, and RYD5 genes. Based on studies of
uteroglobin, the most well-characterized and founding
member of the secretoglobin family, broad putative roles
for these members may involve progesterone binding,immunomodulation, and activation of anti-inflammatory
pathways [10]. Interestingly, HIN-1 downregulation in
lung, pancreatic, and prostate cancers has been shown to
correlate with cellular differentiation status [31], often via
promoter hypermethylation; moreover, loss of UGB has
been reported to be related to advancing grade in prostate
carcinoma [32]. Those results suggest a role for certain
secretoglobins as tumor suppressors, the loss of which cor-
relates with poor prognosis [33]. Interestingly, while HIN-1
and RYD5 localize to chromosomes 19 and 11p15.5, re-
spectively, mammaglobin A/B and lipophilin A/B map to
chromosome 11q13 [5,24], chromosomal alterations of
which have been implicated in poor prognosis in squamous
cell carcinomas of the head / neck [34] and in the patho-
genesis of some breast cancers [35].
Among EOCs, lipophilin B demonstrated not only the
most marked differential gene expression compared to
normal ovary, but also the strongest correlation with
mammaglobin B gene expression. This relationship is not
unanticipated, given that non-glycosylated LipB with a
predicted molecular weight of 7.7 kDa has been shown to
form covalent complexes with the heavily glycosylated
10.5 kDa mammaglobin A [18,27,36]. LipB overexpression
has also been observed in malignant samples from breast,
uterus, cervix, and pituitary [15-18]. Concordance of
mammaglobin A and LipB mRNA expression in breast,
uterine, and cervical cancers has been reported to range
from 56-100% [18,36]; in contrast, no correlation has been
demonstrated in kidney or prostate tissues [18]. Import-
antly, in the present paper we demonstrate for the first
Table 4 Univariate and multivariate analyses of overall survival (OS), disease-free survival (DFS) and progression-free
survival (PFS) in relation to clinical parameters
Univariate survival analysis
OS DFS PFS
Variables N HR 95% CI p N HR 95% CI p N HR 95% CI p
LipB mRNA RQ
Low vs high tertile 92 1.6 0.7-3.3 0.220 64 2.5 1.1-5.6 0.020 88 2.2 1.1-4.3 0.030
LipB IHC
Continuous 92 1.4 0.6-3.3 0.400 67 0.99 0.3-2.4 0.980 91 1.3 0.6-2.8 0.499
LipB IHC
Categoric
IHC = 2 vs IHC≤ 1 92 0.8 0.4-1.6 0.604 67 0.81 0.4-1.6 0.552 91 0.9 0.5-1.7 0.892
IHC = 3 vs IHC≤ 1 1.7 0.7-3.7 0.183 1.15 0.4-2.9 0.764 1.4 0.6-3.1 0.353
Age (years)
>60 vs ≤60 92 2.0 1.1-3.7 0.017 67 1.15 0.6-2.1 0.660 91 1.85 1.1-3.2 0.026
FIGO stage
III-IV vs I-II 92 8.1 2.5-26.2 <0.01 67 6.6 2.5-17.1 <0.01 91 7.8 2.8-21.7 <0.01
Residual tumor (cm)
RT > 0 vs RT = 0 92 3.7 1.8-7.8 <0.01 67 2.4 1.2-4.6 0.010 91 3.4 1.7-6.5 <0.01
Presence of ascites
Yes vs no 92 2.6 1.4-5.1 0.003 67 2.8 1.4-5.4 0.002 91 2.6 1.4-4.7 <0.01
Lymph node involvement




N HR 95% CI p N HR 95% CI p N HR 95% CI p
LipB mRNA RQ
Low vs high tertile 92 1.8 0.9-3.9 0.103 64 3.9 1.7-9.1 0.001 88 2.8 1.4-5.8 0.004
FIGO stage
III-IV vs I-II 92 5.1 1.2-20.5 0.022 67 13.7 4.3-43.2 <0.01 91 5.8 1.7-19.4 0.004
Residual tumor (cm)
RT > 0 vs RT = 0 92 1.1 0.4-2.9 0.799 67 4.9 0.07-0.57 0.003 91 1.02 0.4-2.3 0.964
Presence of ascites
Yes vs no 92 1.6 0.8-3.4 0.180 67 3.3 1.3-8.3 0.009 91 1.8 0.9-3.6 0.095
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tic utility and identifies less aggressive EOC phenotypes.
LipB gene expression correlated with low-grade (p = 0.02)
tumors in our cohort of patients. Remarkably, lower LipB
mRNA levels (low versus high tertiles) are an independent
prognostic marker for decreased disease-free (p = 0.001,
HR = 3.9) and progression-free survival (p = 0.004,
HR = 2.8). These findings are consistent with previous
reports in breast cancer, suggesting that LipB mRNA
overexpression correlates with favourable factors,
such as retention of estrogen-receptor positivity, low-
grade disease and low proliferation rate [16]. To our
knowledge, few papers have investigated the functional
role of LipB overexpression in cancer cells: Sjodin et al.demonstrated that ectopic overexpression of lipophilin B
did not affect the cell proliferation rate of breast carcin-
oma cells in vitro [37], while Tucker et al. reported that it
does not appear to mediate chemoresistance to the estra-
diol derivative estramustine in hormone refractory pros-
tate cancer [38]. Despite undercharacterization of
function, LipB has a well-described role as a tumor-
associated antigen. Serum antibodies to lipophilin B have
been detected in breast and ovarian cancers at titers that
reflect advanced stage and which are absent in normal
controls [39]. This strong response to lipophilin B could
indicate that it may exist in the sera of cancer patients in
the free form, though circulating lipophilin B itself has not
yet been isolated from blood.
Figure 4 Kaplan-Meier survival curves for EOC patients according to LipB mRNA expression. (A) Lower LipB mRNA levels (low versus high
tertiles) showed a significant association with poor DFS (p = 0.02) and (B) shorter PFS (p = 0.03) in the entire cohort of EOC patients.
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level compared to normal ovary, abundance as quanti-
fied by immunohistochemistry failed to demonstrate sig-
nificant prognostic associations with clinicopathological
variables or survival. This result is not completely unex-
pected considering that, in the analysis of our cohort of
patients, the correlation coefficient between LipB mRNA
and protein expression was not significant. Moreover, in
this regard, a discrepancy between mRNA and the encoded
protein abundance in cancer has been previously reported
in several studies [40-42]. This phenomenon is presumably
a result of gene expression biology, suggesting various
levels of regulation during protein synthesis in higher or-
ganisms (posttranscriptional regulation mechanisms in-
volving mRNA stability, translation initiation and protein
stability), likely mediated by the recently discovered class
of biological molecules called non-coding RNAs.
Conclusions
In summary, this is the first quantitative investigation of gene
expression across a comprehensive panel of secretoglobins
in both normal ovaries and EOC tissues. Lipophilin B, a
binding partner for mammaglobin B, emerged as one of the
most differentially expressed secretoglobin family members
in EOC tissues relative to normal ovaries. Consistent
with previous findings by this group, suggesting that
mammaglobin B gene overexpression identifies less ag-
gressive EOC phenotypes with reduced risk of recur-
rence, in the present study lipophilin B also functioned
as an independent prognostic marker for prolonged
disease-free and progression-free survival. In this way,the molecular characterization of secretoglobin expression
by ovarian tumors predicts biologic behaviour and may
eventually contribute to treatment algorithms. Future
studies on Lipophilin B should focus upon elucidation of
biologic function in order to contribute to the broader un-
derstanding of its role in EOC pathogenesis.
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